Abstract: Systems and methods for sleep stage determination are disclosed. Example systems disclosed herein includes a complexity module operable to measure the complexity of regularities in an EEG channel, and a stager operable to output at least one corresponding sleep stage. Some example systems also include monitoring a subject, and determine the subject may have impairment, Alzheimer's disease, or anesthesia problem that is associated with sleep staging problem.

Abstract: Described is the use of L-tryptophan for treating a subject with parasomnia and associated methods of treating a subject with parasomnia. Optionally, the subject may be a child or adolescent between about 3 years of age and 18 years of age. The methods and uses described herein are useful for treating parasomnia in a subject exhibiting sleep walking, sleeptalking, confusional arousals, nightmares, night terrors, rhythmic movement disorder, sleep related eating disorder and/or bruxism. Optionally, subjects are treated with a dose L-tryptophan of about between 700 mg and 5 g per day.

Abstract: According to some aspects, one or more systems and methods for remote testing and diagnostics of at least one patient. In some embodiments, the system comprises at least one personal recorder, configured to record at least one set of test data during at least one self-applied test; at least one data collection point; and a data center configured to analyze the at least one set of the test data received from the at least one data collection point, and generate at least one report.

Abstract: Systems and methods for sleep stage determination are disclosed. Example systems disclosed herein includes a complexity module operable to measure the complexity of regularities in an EEG channel, and a stager operable to output at least one corresponding sleep stage. Some example systems also include monitoring a subject, and determine the subject may have impairment, Alzheimer's disease, or anesthesia problem that is associated with sleep staging problem.

Abstract: Described is the use of L-tryptophan for treating a subject with parasomnia and associated methods of treating a subject with parasomnia. Optionally, the subject may be a child or adolescent between about 3 years of age and 18 years of age. The methods and uses described herein are useful for treating parasomnia in a subject exhibiting sleep walking, sleeptalking, confusional arousals, nightmares, night terrors, rhythmic movement disorder, sleep related eating disorder and/or bruxism. Optionally, subjects are treated with a dose L-tryptophan of about between 700 mg and 5 g per day.

Abstract: According to some aspects, one or more systems and methods for the diagnosis of a medical condition, such as depression, based on an analysis of sleep information. In some embodiments, the diagnostic system includes at least one recorder for recording sleep information about a patient, and at least one analyzer adapted to analyze the sleep information and determine whether the patient is experiencing the medical condition.